Conference Call with Marksans Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Marksans Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Operating revenue stood at Rs 708.5 crore., up by 26.5% YoY driven growth across key markets, led by US region Gross profit stood at Rs 383.2 crore., up by 32.1% YoY, with a gross margin expansion of 228 bps YoY to 54.1%. Growth is attributed to softening of raw material prices and a better product mix. EBITDA stood at Rs 125.8 crore. up by 14.7% YoY, with a margin of 17.8% EPS is at Rs 2.0, an incroreease of 15.7% FY25 Financial Highlights: Operating revenue stood at Rs 2,622.8 crore., up by 20.5% YoY driven by growth across all markets US business grew by 34.7% YoY UK & Europe grew by 9.2% YoY Australia & New Zealand grew by 15.5% YoY Gross profit came in at Rs 1,479.1 crore., up by 29.8% YoY, with a gross margin of 56.4% EBITDA stood at Rs 528.6 crore., up by 15.3%, with an EBITDA margin of 20.2% EPS grew by 21.3% YoY to Rs 8.4 Mark Saldanha, Managing Director of the Company said “We are pleased to announce another year of robust performance; we have achieved highest ever annual revenues and profits. In FY25, we witnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing Rs 2000 crore in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looking forward, we continue to strengthen our foundation by increasing the capacity and strengthening our product pipeline. We are optimistic about building on this momentum and create more value for our stakeholders in the coming years” Result PDF
Conference Call with Marksans Pharma Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Marksans Pharma announced Q3FY25 results Operating revenue stood at Rs 681.8 crore, up by 16.3% YoY driven growth across key markets, led by US region. Gross profit stood at Rs 383.5 crore, up by 22.4% YoY, with a gross margin expansion of 279 bps YoY to 56.2%. Growth is attributed to softening of raw material prices and a better product mix. EBITDA stood at Rs 138.8 crore up by 4.3% YoY, with a margin of 20.4%. EPS grew by 25.5% YoY to Rs 2.3. Mark Saldanha, Managing Director of the Company said: “We are delighted to announce an all-time high quarterly PAT, driven by robust growth of 16.3% YoY in Q3 revenue. Revenue growth was led by the US region, which witnessed 37% YoY growth, followed by UK, which improved during the quarter. Improved product mix and softer raw material prices compared to the previous year led to gross margin expansion of 279bps YoY. We witnessed some headwinds in terms of EBITDA margin due to our investments in the acquired facility and increased freight costs during the quarter. Looking ahead, we anticipate growth to continue in the coming quarters augmented by planned new launches and further ramp up of the TEVA facility.” Result PDF
Pharmaceuticals company Marksans Pharma announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Operating revenue stood at Rs 641.9 crore, up by 20.8% YoY driven by strong performance across all key markets, led by US and followed by ANZ. Gross profit stood at Rs 383.5 crore, up by 37.7% YoY, with a gross margin expansion of 732 bps to 59.7%. Growth is attributed to continued softening of raw material prices and a better product mix. EBITDA stood at Rs 135.7 crore up by 19.1%, with a margin of 21.1%. EPS grew by 15.8% YoY to Rs 2.1. H1FY25 Financial Highlights: Operating revenue stood at Rs 1,232.5 crore, up by 19.5% YoY driven by growth across all key markets, new product launches and share gains with existing customers. US business grew by 33.5% YoY. UK & Europe grew by 8.5% YoY. Australia & New Zealand grew by 20.7% YoY. Gross profit came in at Rs 712.4 crore, up by 33.0% YoY, with a gross margin of 57.8%. EBITDA stood at Rs 264.1 crore, up by 22.3%, with an EBITDA margin of 21.4%. EPS grew by 21.7% YoY to Rs 4.1 Mark Saldanha, Managing Director, said: “Q2 marks a strong performance on back of a robust Q1. Growth trajectory improved further with revenue growth of 21% YoY. We are happy to share that this growth was broad based across all our key markets, led by the US market and also driven by increased market share. We continue to witness favourable raw material prices and improved product mix, thereby leading to a gross margin expansion of 732bps YoY and an all-time high quarterly EBITDA of Rs 135.7 crore. We anticipate stronger performance in the coming quarters due to our upcoming new launches, the onset of the winter season and scaling up of the TEVA facility.” Result PDF